Multifaceted roles of CCL20 (C-C motif chemokine ligand 20): mechanisms and communication networks in breast cancer progression

Louis Boafo Kwanti\textsuperscript{a}, Shujing Wang\textsuperscript{a,b}, Youjing Sheng\textsuperscript{a}, and Qiang Wu\textsuperscript{a,c}

\textsuperscript{a}Department of Pathology, School of Basic Medical Science, Anhui Medical University, Hefei, PR China; \textsuperscript{b}Department of Immunology, School of Basic Medical Science, Anhui Medical University, Hefei, PR China; \textsuperscript{c}Department of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei, PR China

ABSTRACT
Emerging studies have demonstrated notable roles of CCL20 in breast cancer progression. Based on these findings, CCL20 has become a potential therapeutic target for cancer immunotherapy. Accordingly, studies utilizing monoclonal antibodies to target CCL20 are currently being experimented. However, the existence of cytokine network in the tumor microenvironment collectively regulates tumor progression. Hence, a deeper understanding of the role of CCL20 and the underlying signaling pathways regulating the functions of CCL20 may provide a novel strategy for therapeutic interventions. This review provides the current knowledge on how CCL20 interacts with breast cancer cells to influence tumor progression via immunosuppression, angiogenesis, epithelial to mesenchymal transition, migration/invasion and chemoresistance. As a possible candidate biomarker, we also reviewed signal pathways and other factors in the tumor microenvironment regulating the tumor-promoting functions of CCL20.

These new insights may be useful to design new potent and selective CCL20 inhibitors against breast cancer in the future.

1. Introduction
Breast cancer continues to be the leading cause of cancer-related deaths among women \([1,2]\), primarily as a result of metastasis. Conventionally, breast cancer metastasis is mediated by the interaction between chemokine receptors on cancer cells and chemokines expressed at the metastasis site \([3]\). Chemokines are low molecular weight (8–14 kDa) cytokines that are classified as CC, CXC, CX3C and C chemokines \([4]\).
Chemokines are well known to play essential roles in the recruitment of immune cells and the development of lymphoid tissues. They also regulate the recruitment and trafficking of leukocytes during homeostasis and inflammation [5–7]. Inflammatory chemokines are released to induce leukocyte infiltration to inflammatory site [8]. On the other hand, homeostatic chemokines are expressed in tissues and play essential roles in adaptive immunity [9]. Beyond these physiological roles, emerging studies have highlighted the indispensable role of chemokines and their receptors in tumor progression [7,10,11]. It has become evident that chemokines regulate several oncogenic processes, including host immune response, tumor growth, angiogenesis, metastasis and chemoresistance [3,12].

CCL20, the only chemokine ligand for C-C motif chemokine ligand-receptor 6 (CCR6), is a member of the CC family and the alpha subfamily chemokines [4,13–15]. Structurally, CCL20 contains four exons and three introns at their junctions which differ from other members of the CC chemokines [16]. The available evidence supports the role of CCL20 in the progression of inflammatory diseases [17,18], including cancers [19–23]. These advances have led to the recognition of CCL20 as a promising candidate for cancer immunotherapy. Therefore, an in-depth understanding of the roles and regulatory mechanisms of CCL20 are relevant for the development of cancer drugs with improved efficacies. This review summarized the emerging roles of CCL20 and the underlying signaling regulating the tumor-promoting functions of CCL20 in breast cancer. The synergistic effect of CCL20 and other factors in the tumor microenvironment have also been discussed.

### 2. Role of CCL20 in breast cancer progression

It is well established that tumor cells express high levels of chemokines. Chemokines recruit and signal immune cells to create a favorable environment for cancer cells [24]. Previously, CCL20 was known for its antimicrobial activity [25] and involvement in autoimmune diseases such as inflammatory bowel disease [26], rheumatoid arthritis [27] and psoriasis [28]. However, emerging evidence strongly suggests association between CCL20 and tumor progression in several solid tumors. Importantly, several established roles, including tumor growth, inhibition of apoptosis, angiogenesis and therapeutic resistance have been linked to the expression of CCL20 in the tumor microenvironment [29,30]. In the remaining section, the roles of CCL20 in immunosuppression, angiogenesis, epithelial to mesenchymal transition (EMT), migration/invasion and chemo resistance have been discussed (Table 1).

#### 2.1. Immunosuppression

The ability of cancer cells to escape from the host immune response is a hallmark of cancer

| Mechanism       | Function                                                                 | Reference |
|-----------------|--------------------------------------------------------------------------|-----------|
| Immunosuppression | CCL20 via CCR6+ Tregs decreased the expression of IFN-γ secreted by CD8+ T cells. CCL20 recruited immature dendritic cells into tumor tissues to impair immune response. | [42,46] |
| EMT             | CCL20 upregulated vimentin and N-cadherin but downregulated E-cadherin and ZO-1. | [23]      |
| Migration and Invasion | CCL20 promoted the migration and invasion of triple-negative breast cancer cells. Silencing CCL20 by intraperitoneal injection of anti-CCL20 antibody inhibited osteolytic bone metastasis in mice inoculated with MDA-MB-231 cells. | [86, 87] |
| Angiogenesis    | Recombinant human CCL20 induced VEGF expression.                          | [23]      |
| Tumor growth    | Recombinant human CCL20 increased the proliferation of breast cancer cells (MDA-MB-231 and SUM159 cells). Expression of CCL20 in MDA-MB-468 cell lines recruited macrophages into tumors to promote their growth. | [57,87] |
| Chemoresistance | CCL20 promotes renewal and maintenance of cancer stem cells in triple-negative breast cancer cells. CCL20 upregulated ABCB1 to promote chemoresistance to taxanes. | [92]      |
progression. In these processes, immune effector cells with anti-tumor functions acquire protumor functions [31,32]. Accumulating studies have shown that forkhead/winged-helix transcription factor P3 (FOXP3) infiltrated into tumor tissues plays vital role in tumor immunity. Their presence impairs anti-tumor immune response of the host and promotes tumor progression in several solid tumors including breast cancer [33–35]. Furthermore, the number of tumor-infiltrating FOXP3+ Treg in tumor tissue increases with tumor progression [36]. Evidence has shown that Tregs are induced to invade tumor tissues by CCL20. Jinlin et al. has demonstrated that CCL20 promotes regulatory T cells (Tregs) recruitment and cancer progression in mice implanted with colorectal cancer cells [37]. According to Kang et al., marked infiltration of Tregs induced by CCL20 potentiates disease progression in hepatocellular carcinoma [38]. In a recent study, high expression of CCL20 was associated with an increased homing of FOXP3 into breast cancer tissues. The study further noted that the concomitant expressions of these markers were associated with poor prognostic outcomes in breast cancer patients [39]. Besides the chemotactic functions, CCL20 cooperates with CCR6 to suppress the functions of CD8 T cells. It is well known that the integral role played by CD8 T cells in antitumor immunity is mainly dependent on the secretion of cytotoxic molecules or effector cytokines [40]. Unsurprisingly, low levels of these effector cytokines on CD8 + T cells have been associated with immunosuppression [41]. Along this line, a study has noted that high infiltration of CCR6 Tregs promotes immunosuppression and disease progression in breast cancer by suppressing IFN-γ on CD8 + T cells [42].

It has been reported that dendritic cells infiltrated into tumors perform opposing functions depending on their maturation stage [43]. Immature dendritic cells (iDCs) present antigens to T cells, and further induce immune tolerance, including generation of inducible Tregs cells and anergy of T cells. On the other hand, mature dendritic cells prime CD4 and CD8 T cells, activate B cells and initiate the activation of an adaptive immune response [44]. Beyond recruiting Tregs, CCL20 also fosters immunosuppression through the recruitment of dendritic cells. According to Bell et al., high expression of CCL20 was associated with increased infiltration of immature dendritic cells into breast cancer tissues [45]. Dendritic cell infiltrated into tumor tissues is associated with poor prognostic outcomes in breast cancer patients [46]. According to a mechanistic study, tumor derived CCL20 induces the infiltration of immature dendritic cells with two distinct phenotypes that differ in their capacity to activate T lymphocytes [47]. However, the mechanism of reprogramming dendritic cells by CCL20 remains unknown and warrants further studies in breast cancer.

### 2.2. Angiogenesis

Like normal cells, adequate oxygen supply to tumor cells is critical for their survival [48,49]. CCL20 plays important role in angiogenesis and vascular remodeling [50,51] by stimulating angiogenic factors such as vascular endothelial growth factor (VEGF). VEGF, a crucial driver of angiogenesis, enhances tumor vessel dilation, permeability and leaking [52]. In principle, the action of VEGF is potentiated by the hypoxic nature of the tumor microenvironment, where the oxygen deficit stimulates the expression of hypoxia-inducible factor-alpha 1 (HIF-1α) [53,54]. Emerging evidence shows that the treatment of healthy breast cells with recombinant human CCL20 upregulates the protein and mRNA expression of VEGF [23]. In aortic ring assay, a robust method for determining angiogenesis [55], CCL20 directly induced angiogenic microvessel aortic sprouting in primary breast cancer cells [23]. In other experimental settings, CCL20 promoted angiogenesis [51] by inducing endothelial cell proliferation and the formation of new blood vessels [56]. These outcomes were consistent in a study where the neutralization of CCL20 inhibited angiogenesis in hepatocellular carcinoma [51].

Immune cells have been identified to play essential roles in angiogenesis. Among them, a link between CCL20 and tumor-associated macrophages (TAMs) has been established. As chemokine, CCL20 plays a substantial role in the
recruitment of several immune cells, including macrophages. In a recent study, silencing CCL20 in tumor conditioned media from MDA-MB-231 cells attenuated the recruitment of macrophages into tumor-bearing mice [57]. Although the authors did not provide a regulatory mechanism of CCL20 induced TAMs in angiogenesis, TAMs have been demonstrated to promote angiogenesis by supplying tumor cells with angiogenic factors [58].

2.3. Epithelial-mesenchymal transition (EMT)

In certain key biological processes such as tissue remodeling, embryonic development, wound repair, and tumorigenesis, epithelial cells with rigid structures acquire a flexible phenotype that allows cell migration and movement. This morphogenetic transformation is known as epithelial-mesenchymal transition [59]. Experimentally, EMT is marked by loss of E-cadherin expression (epithelial phenotype) and increased expression of vimentin and N-cadherin (mesenchymal phenotype) [60,61]. EMT is known to play important role in the oncogenesis processes by enhancing the ability of tumor cells to access blood and migrate to establish metastases [62–64]. Significantly, the induction of EMT is associated with tumor aggressiveness and poor prognostic outcomes in breast cancer patients [65,66]. The role of chemokines in EMT induction in epithelial tumor cells has been investigated [67,68], and the evidence has implicated CCL20 in such processes [69]. In vitro study has demonstrated that direct coculture between healthy breast cells and recombinant human CCL20 upregulates vimentin and N-cadherin, which are characteristics of EMT. To further establish the involvement of CCL20 in EMT, blocking CCL20 decreased the expression of vimentin and N-cadherin [23]. Besides the aforementioned EMT markers, EMT inducers can also enhance the expression of metalloproteinases (MMPs) [70]. Generally, MMPs degrade the extracellular matrix and basement membrane [71–73] to facilitate tumor metastasis [74,75]. According to Marsigliante et al., induction of EMT by CCL20 is associated with high expression of MMP-2 and MMP-9 in breast cancer cells [23].

The process of EMT is characterized by the activation of several key transcriptional factors, including Twist, Snail (SNAI1), Slug (SNAI2), zinc finger E-box-binding (ZEB) and basic helix-loop-helix (bHLH) [76–78]. These EMT transcription factors reconstruct a favorable tumor micro-environment to facilitate immune evasion [79]. It has been demonstrated that blockade of Snail in healthy breast cells treated with CCL20 restores the expression of E-cadherin and zonula occludens-1(ZO-1) but downregulates that of N-cadherin and vimentin [23], suggesting the involvement of Snail in CCL20 driven EMT.

2.4. Migration and invasion

The migration of tumor cells from their primary organ is essential for the metastatic dissemination of tumors. This process largely depends on the biochemical and physical properties of cells and the extracellular matrix [80]. Chemokines and their receptors directly affect the invasive abilities of tumor cells by binding to the glycosaminoglycans in the extracellular matrix [81]. In several solid tumors, CCL20 has been identified to potentiate the migration and invasion of tumor cells [82–85]. Using adipocyte conditioned media (ACM) in coculture with MDA-MB-231 cells, Kim et al. demonstrated a higher invasive ability of MDA-MB-231 cells than MDA-MB-231 cells cultured alone. The study further noted that migration of MDA-MB-231 cells was associated with increased production of CCL20 in adipocyte-conditioned media [86]. Lee et al. investigated the effect of chemokines on the migratory and invasive abilities of breast cancer cells and found CCL20 to play key role in such processes. More importantly, silencing CCL20 by intraperitoneal injection of anti-CCL20 antibody inhibited osteolytic bone metastasis in mice inoculated with MDA-MB-231 cells [87].

Degradation of extracellular matrix by protease such as MMPs has been shown to play pivotal roles in tumor invasion [88,89]. To gain insights into CCL20 mediated invasion mechanisms, Lee et al. determined the expression of MMPs in triple-negative and luminal breast cancer cell lines.
The expression of CCL20 in triple-negative breast cancer cell lines (MDA-MB-231 and BT549) facilitated tumor migration by upregulating MMP1, MMP-2 and MMP-9. On the contrary, CCL20 in MCF-7 and ZR-75-1 cell lines showed no significant effect on tumor invasion and expression of MMPs [87]. More interestingly, these observations have been noted in gastric [90] and thyroid [91] cancers where CCL20 enhanced the migration and invasion of tumor cells through MMPs. These data strongly suggest that CCL20, through MMPs, exerts more significant effects in metastatic triple-negative breast cancer cells [92] than less invasive luminal breast cancer cells.

2.5. Chemoresistance

During cancer treatment, surviving cells reemerge as more aggressive cells to limit further treatment options. This phenomenon has been a challenge in cancer treatment and patient survival [93]. Drug resistance has been linked to increased immunosuppressive cells, chemokines, and cytokines [94–96]. Changes in the levels of cytokines during chemoresistance have been reported to favor tumor growth and disease progression [97]. Evidence implicating chemokines in drug resistance has been obtained through serum evaluation of chemokines and mechanistic studies (in vivo and in vitro) [98]. According to Goulin et al., high serum levels of chemokine (C-X-C motif) ligand 13 (CXCL-13) in colorectal patients are associated with 5-fluorouracil drug resistance [99]. Chen et al. also evaluated serum levels of CCL20 before, during and after treatment of taxanes in breast cancer. The study found high serum levels of CCL20 during and after taxanes treatment, especially in patients with non-pathologic complete response [92]. Emerging evidence supports a link between cancer stem cells renewal and chemotherapeutic resistance [100,101]. These processes alter genes controlling cell cycle and apoptosis [102]. Chen et al. have shown that CCL20 fosters the resistance of breast cells to taxanes by upregulating stem cell genes such as NANOG, octamer-binding transcription factor 4 (OCT4), and sex-determining region Y-box 2 (SOX2) [92]. In another experimental study, CCL20 increased the expression of OCT4 to promote resistance of ovarian cancer cells to paclitaxel [103]. Besides the upregulation of cancer stem cell genes, enhanced efflux of drugs plays crucial role in therapeutic resistance [104]. Largely, drug efflux is potentiated by the expression of transmembrane transporters, including ATP-binding cassette subfamily B member 1 (ABCB1) [104]. Chen et al. investigated the association between CCL20 and ABCB1. The researchers found that overexpression of CCL20 in triple-negative breast cancer cell lines induced high expression of ABCB1, which further promoted taxanes resistance [92]. Collectively, targeting CCL20 could promote chemotherapeutic efficacy in breast cancer.

3. Signal pathways regulating CCL20 in breast cancer

The signal pathways regulating the actions of CCL20 in breast cancer are diverse and complex, where the activation of a pathway signals several other downstream pathways. Besides the well-known functions of nuclear factor-kB (NF-kB) in regulating immune response and inflammation [105,106], increasing evidence supports their involvement in several oncogenic processes [105,107]. They are known to regulate the expression of proinflammatory genes, including those encoding chemokines and cytokines [106]. In triple negative breast cancer cell lines, silencing NF-kB reduced the expression of stem cell genes and ABCB1. Consequently, taxanes resistance induced by CCL20 was reversed. Notably, these activities of NF-kB were regulated through protein kinase c (PKC) and mitogen-activated protein kinase (MAPK) signaling pathways [92]. Kim et al. showed in triple-negative breast cancer cell lines that the inhibition of NF-kB downregulates the expression of CCL20 in adipocyte conditioned media [86]. In a related study, the inhibition of NF-kB, PKC and mammalian target of rapamycin (mTOR) downregulated the expression of vimentin and N-cadherin induced by CCL20, suggesting the involvement of these kinases in CCL20-driven EMT [23]. Evidence provided by Marsigliante et al. showed that PKC, Src and phosphoinositide 3-kinase (PI3K) are key regulators of CCL20-driven angiogenesis in breast cancer (Figure 1) [23].
Notch signaling controls several cellular processes, such as cell-fate specialization, maintenance of stem cells, motility, proliferation and survival. However, the abnormal expression of Notch influences the oncogenic processes in breast cancer through these activities [108]. Notch signaling regulates oncogenic activities [109] and controls the expression of several target genes, including CCL20 [110]. In a recent study exploring downstream regulators of notch signaling in the metastasis processes of breast cancer, silencing notch in MDA-MB-231 cell lines significantly inhibited the mRNA expression of CCL20 [111]. Although this study did not establish any tumor-promoting effect of CCL20 via notch signaling, the independent role of notch and CCL20 makes it logical to assume that CCL20 may influence tumor progression via notch pathway in breast cancer.

4. Communication between CCL20 and other factors in breast cancer tumor microenvironment

Beyond the direct role of CCL20 in influencing tumor progression, several studies have highlighted the synergistic effect of CCL20 and other cytokines in promoting tumor progression. In colorectal cancer, CCL20 in collaboration with C-X-C motif chemokine ligand (CXCL8), promoted tumor metastasis through EMT [69]. In non-small-cell-lung-cancer (NSCLC), interleukin 17 (IL-17) induced the expression of CCL20, and their concomitant expression promoted the disease progression [112]. In breast cancer, evidence has shown that the tumor-promoting functions of CCL20 can be regulated by human antigen R (HuR), Cbp/P300 interacting transactivator with Glu/Asp-rich carboxyl-terminal domain 2 (CITED2) and tumor necrosis factor-alpha (TNF-α) (Table 2).

Human antigen R (HuR), a member of the embryonic lethal abnormal vision, binds to the 3’ untranslated regions of the target mRNA to enhance their stability. Overexpression of HuR has been reported to modulate the oncogenic processes by upregulating the expression of growth factors [113,114]. In breast cancer, HuR regulated the expression of CCL20 to promote invasion of MDA-MB-231 cells and osteolytic bone metastasis in tumor-bearing mice. Furthermore, silencing either CCL20 or HuR in triple-negative breast cell lines significantly abrogated the tumor-promoting effect. These suggest that although HuR can upregulate the expression of CCL20, they exhibit a synergetic effect on tumor behavior [87].

![Figure 1. Multifaceted roles of CCL20 in breast cancer progression. CCL20 recruits dendritic cells and CCR6 Tregs to impair the function of T cells (a). CCL20 induces VEGF expression to foster angiogenesis (b). CCL20 activates Snail to upregulates mesenchymal markers and downregulates epithelial markers (c). CCL20 promotes the migration and invasion of cancer cells. CCL20 induces stem cell genes and ABCB1 expression to enhance drug resistance (e).](image-url)
CITED2 is a transcription co-factor that plays vital role in various fundamental cellular processes during development and differentiation. However, mounting evidence suggests a potential role of CITED2 in the development and progression of several human malignancies, including breast cancer [115,116]. According to previous studies, CITED2 regulates the expression of several growth factors such as transforming growth factor-beta (TGFβ) [115], interleukin 11 (IL-11), interleukin 1 beta (IL-1β) [117] and HIF-1α [118] to promote breast cancer progression. In breast cancer, the regulatory effect of CITED2 on CCL20 has been reported by Jayaraman et al. According to the authors, silencing CITED2 in MDA-MB-231 cell line attenuates the recruitment of macrophages mediated by CCL20 [57].

TNF-α is a crucial inflammatory cytokine in the tumor microenvironment that plays active role in all stages of breast cancer progression [119]. TNF-α regulates the expression of CCL20 in various pathological conditions such as autoimmune hepatitis [120] and psoriasis [28]. In breast cancer, Kim et al. investigated the factor responsible for upregulating the expression of CCL20 in MDA-MB-231 cell line. The authors showed that silencing TNF-α using TNF-α neutralizing antibody abolished the expression of CCL20 induced by adipocyte conditioned media [86].

Despite the limited evidence in this area, a better understanding of the communication between CCL20 and other factors in the tumor microenvironment will provide insights into tumor biology. This will be beneficial in developing a dual-antagonist combination treatment for breast cancer.

5. Conclusion

Collectively, this review suggests that CCL20 plays essential roles in the oncogenesis processes of breast cancer. However, CCL20 appears to engage in a complex interaction with other factors in the tumor microenvironment. Hence, as research advances, it would be better to understand the communication networks between CCL20 and other factors in the tumor microenvironment. Notably, there is the need to highlight and understand the key factors regulating the tumor-promoting effects of CCL20 in tumor progression. As we gain such new insights, disrupting CCL20 promoting networks could provide novel therapeutic strategies for breast cancer treatment.

Acknowledgements

We acknowledge the funding support from The Academic and Technological Leaders and Reserves Foundation of Anhui Province (2019H230) and China Scholarship Council (2020-1417).

Article Highlights

(1) The roles of CCL20 in breast cancer progression have been summarized.
(2) Communication between CCL20 and other factors in breast cancer tumor microenvironment have been reported.
(3) Targeting CCL20 can be a useful strategy for breast cancer treatment.

Author Contributions

Louis BK drafted and revised the manuscript; SJ Wang and Youjing Sheng revised the manuscript; Q Wu provided overall research supervision, revised the manuscript and funded the work.
Disclosure statement

Authors declare there is no competing interest.

Funding

This work was supported by the China Scholarship Council [2020-1417]; The Academic and Technological Leaders and Reserves Foundation of Anhui Province of the 2019 academic year [2019H230].

References

[1] Siegel RL, Miller KD, Jemal A, et al. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
[2] Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66.
[3] Rizeq B, Malki MI. The role of CCL21/CCR7 chemokine axis in breast cancer progression. Cancers (Basel). 2020;12(4). DOI:10.3390/cancers12041036.
[4] Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12(2):121–127.
[5] Zhao L, Xia J, Wang X, et al. Transcriptional regulation of CCL20 expression. Microbes Infect. 2014;16(10):864–870.
[6] Ghadjar P, Rubie C, Aebersold DM, et al. The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. Int J Cancer. 2009;125(4):741–745.
[7] Mukaida N, Sasaki S-I, Baba T, et al. Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment. Mediators Inflamm. 2014;2014:170381.
[8] Griffith JW, Sokol CL, Luster AD, et al. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014;32(1):659–702.
[9] Zlotnik A, Burkhartd AM, Homey B, et al. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 2011;11(9):597–606.
[10] Nagarsheth N, Wicha MS, Zou W, et al. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–572.
[11] Do HTT, Lee CH, Cho J, et al. Chemokines and their receptors: multifaceted roles in cancer progression and potential value as cancer prognostic markers. Cancers (Basel). 2020;12(2):287.
[12] Reyes ME, de La Fuente M, Hermoso M, et al. Role of CC chemokines subfamily in the platinum drugs resistance promotion in cancer. Front Immunol. 2020;11(901). DOI:10.3389/fimmu.2020.00901.
[13] Osuala KO, Sloane BF. Many roles of CCL20: emphasis on breast cancer. Postdoc J. 2014;2(3);7–16.
[14] Ranasinghe R, Eri R. Modulation of the CCR6-CCL20 axis: a potential therapeutic target in inflammation and cancer. Medicina (B Aires). 2018;54(5):88.
[15] Frick VO, Rubie C, Keilholz U, et al. Chemokine/chemokine receptor pair CCL20/CCR6 in human colorectal malignancy: an overview. World J Gastroenterol. 2016;22(2):833–841.
[16] Nelson RT, Boyd J, Gladue RP, et al. Genomic organization of the CC chemokine MIP-3α/CCL20/LARC/EXODUS/SCYA20, showing gene structure, splice variants, and chromosome localization. Genomics. 2001;73(1):28–37.
[17] Scheerens H, Hessel E, De Waal-malefyt R, et al. Characterization of chemokines and chemokine receptors in two murine models of inflammatory bowel disease: IL-10/- mice and Rag-2/- mice reconstituted with CD4+CD45RBhigh T cells. Eur J Immunol. 2001;31(5):1465–1474.
[18] Atreya R, Neurath MF. Chemokines in inflammatory bowel diseases. Dig Dis. 2010;28(3):386–394.
[19] Liu B, Jia Y, Ma J, et al. Tumor-associated macrophage-derived CCL20 enhances the growth and metastasis of pancreatic cancer. Acta Biochim Biophys Sin (Shanghai). 2016;48(12):1067–1074.
[20] Wang D, Yang L, Wu W, et al. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemo resistance via FOXO1/CEBPB/NF-kappaB signaling. J Immunother Cancer. 2019;7(1):215.
[21] Liu W, Wang W, Wang X, et al. Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20-CCR6 axis. Cancer Lett. 2020;472:59–69.
[22] Du D, Liu Y, Qian H, et al. The effects of the CCR6/CCL20 biological axis on the invasion and metastasis of hepatocellular carcinoma. Int J Mol Sci. 2014;15(4):6441–6452.
[23] Marsiglione S, Vetrungo C, Muscella A, et al. Paracrine CCL20 loop induces epithelial-mesenchymal transition in breast epithelial cells. Mol Carcinog. 2016;55(7):1175–1186.
[24] Nagarsheth N, Wicha MS, Zou W, et al. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–572.
[25] Yang D, Chen Q, Hoover DM, et al. Many chemokines including CCL20/MIP-3α display antimicrobial activity. J Leukoc Biol. 2003;74(3):448–455.
[26] Kaser A, Ludwiczek O, Holzmann S, et al. Increased expression of CCL20 in human inflammatory bowel disease. J Clin Immunol. 2004;24(1):74–85.
[27] Matsui T, Akahoshi T, Namai R, et al. Selective recruitment of CCR6-expressing cells by increased production of MIP-3α in rheumatoid arthritis. Clin Exp Immunol. 2001;125(1):155–161.
[28] Furue K, Ito T, Tsuji G, et al. The CCL20 and CCR6 axis in psoriasis. Scand J Immunol. 2020;91(3):12846.
[29] Kadomoto S, Izumi K, Mizokami A, et al. The CCL20-CCR6 axis in cancer progression. Int J Mol Sci. 2020;21(15):5186.
[30] Guo I, Situ HL, Wang ZY, et al. Mechanism of jinrong granule in inhibiting the invasion of breast cancer cells by the CXCL-1-CXCR2/CCL20 pathway. J Biol Regul Homeost Agents. 2020;34(3):969–976.

[31] Vesely MD, Kershaw MH, Schreiber RD, et al. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29(1):235–271.

[32] Chow MT, Luster AD. Chemokines in cancer. Cancer Immunol Res. 2014;2(12):1125–1131.

[33] Aruga T, Suzuki E, Saji S, et al. A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. Oncol Rep. 2009;22(2):273–278.

[34] Bates GI, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006;24(34):5373–5380.

[35] Gobert M, Treilleux I, Bendriss-Vermare N, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009;69(5):2000–2009.

[36] Li L, Yang C, Zhao Z, et al. Skewed T-helper (Th)1/2- and Th17/T regulatory-cell balances in patients with renal cell carcinoma. Mol Med Rep. 2015;11(2):947–953.

[37] Liu J, Zhang N, Li Q, et al. Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PloS One. 2011;6(4):e19495.

[38] Chen KJ, Lin SZ, Zhou L, et al. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PloS One. 2011;6(9):e24671.

[39] Zhao X, Li Y, Wang X, et al. Synergistic association of FOXP3+ tumor infiltrating lymphocytes with CCL20 expressions with poor prognosis of primary breast cancer: a retrospective cohort study. Medicine (Baltimore). 2019;98(50):e18403.

[40] Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol. 2002;20:323–370.

[41] Chikamatsu K, Sakakura K, Whiteside TL, et al. Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck. Head Neck. 2007;29(2):120–127.

[42] Xu L, Xu W, Qiu S, et al. Enrichment of CCR6+Foxp3+ regulatory T cells in the tumor mass correlates with impaired CD8+ T cell function and poor prognosis of breast cancer. Clin Immunol. 2010;135(3):466–475.

[43] Michea P, Noël F, Zakine E, et al. Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific. Nat Immunol. 2018;19(8):885–897.

[44] Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5(4):296–306.

[45] Bell D, Chomarat P, Broyles D, et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med. 1999;190(10):1417–1426.

[46] Treilleux I, Blay J-Y, Bendriss-Vermare N, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res. 2004;10(22):7466–7474.

[47] Thomachot MC, Bendriss-Vermare N, Massacrier C, et al. Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1a/CD86–Langerin+ and CD1a+CD86+Langerin+ phenotypes. Int J Cancer. 2004;110(5):710–720.

[48] De Palma M, Biziato D, Petrova TV, et al. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017;17(8):457–474.

[49] Mao Y, Wang Y, Dong L, et al. Hypoxic exosomes facilitate angiogenesis and metastasis in esophageal squamous cell carcinoma through altering the phenotype and transcriptome of endothelial cells. J Exp Clin Cancer Res. 2019;38(1):389.

[50] Hippe A, Braun SA, Oláh P, et al. EGFR/Ras-induced CCL20 production modulates the tumour microenvironment. Br J Cancer. 2020;123(6):942–954.

[51] He H, Wu J, Zang M, et al. CCR6(+)- B lymphocytes responding to tumor cell-derived CCL20 support hepato-cellular carcinoma progression via enhancing angiogenesis. Am J Cancer Res. 2017;7(5):1151–1163.

[52] Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249–257.

[53] Jin P, Shin SH, Chun YS, et al. Astrocyte-derived CCL20 reinforces HIF-1-mediated hypoxic responses in glioblastoma by stimulating the CCR6-NF-kappaB signaling pathway. Oncogene. 2018;37(23):3070–3087.

[54] Ye L-Y, Chen W, Bai X-L, et al. Hypoxia-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma induces an immunosuppressive tumor microenvironment to promote metastasis. Cancer Res. 2016;76(4):818.

[55] Nicosia RF, Zhu WH, Fogel E, et al. A new ex vivo model to study venous angiogenesis and arterio-venous Anastomosis formation. J Vasc Res. 2005;42(2):111–119.

[56] Benkheil M, Van Haele M, Roskams T, et al. CCL20, a direct-acting pro-angiogenic chemokine induced by hepatitis C virus (HCV): potential role in HCV-related liver cancer. Exp Cell Res. 2018;372(2):168–177.

[57] Jayaraman S, Doucet M, Kominsky SL, et al. CITED2 attenuates macrophage recruitment concurrent with the downregulation of CCL20 in breast cancer cells. Oncol Lett. 2018;15(1):871–878.
[58] Bruno A, Pagani A, Pulze L, et al. Orchestration of angiogenesis by immune cells. Front Oncol. 2014;4 (131). DOI: 10.3389/fonc.2014.00131.

[59] Pastushenko I, Blanpain C. EMT transition States during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–226.

[60] Zhang Z, Zhang Y, Qiu Y, et al. Human/eukaryotic ribosomal protein L14 (RPL14/eL14) overexpression represses proliferation, migration, invasion and EMT process in nasopharyngeal carcinoma. Bioengineered. 2021;12(1):2175–2186.

[61] Li T, Zhao N, Lu J, et al. Epigallocatechin gallate (EGCG) suppresses epithelial-mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/smads signaling pathways. Bioengineered. 2019;10(1):282–291.

[62] Roche J. The epithelial-to-mesenchymal transition in cancer. Cancers (Basel). 2018;10(2):52.

[63] Nieto MA, Huang RY, Jackson RA, et al. EMT: 2016. Cell. 2016;166(1):21–45.

[64] Whiteside TL. Tumor-derived exosomes and their role in cancer progression. Adv Clin Chem. 2016;74:103–141.

[65] Liu T, Zhang X, Shang M, et al. Dysregulated expression of slug, vimentin, and E-cadherin correlates with poor clinical outcome in patients with basal-like breast cancer. J Surg Oncol. 2013;107(2):188–194.

[66] Tran DD, Corsa CA, Biswas H, et al. Temporal and spatial cooperation of snail1 and twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence. Mol Cancer Res. 2011;9(12):1644–1657.

[67] Yu Y, Wang W, Lu W, et al. Inhibin β-A (INHBA) induces epithelial–mesenchymal transition and accelerates the motility of breast cancer cells by activating the TGF-β signaling pathway. Bioengineered. 2021;12(1):4681–4696.

[68] Wu H-T, Zhong H-T, Li G-W, et al. Oncogenic functions of the EMT-related transcription factor ZEB1 in breast cancer. J Transl Med. 2020;18(1):51.

[69] Cheng X-S, Li Y-F, Tan J, et al. CCL20 and CXCL8 synergize to promote progression and poor survival outcome in patients with colorectal cancer by collaborative induction of the epithelial-mesenchymal transition. Cancer Lett. 2014;348(1–2):77–87.

[70] Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15(2):201–212.

[71] Martins LM, de Melo Escorcio Dourado CS, Campos-Verdes LM, et al. Expression of matrix metalloproteinase 2 and 9 in breast cancer and breast fibroadenoma: a randomized, double-blind study. Oncotarget. 2019;10(64):6879–6884.

[72] Huang H. Matrix metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 biosensors: recent advances. Sensors (Basel). 2018;18(10):3249.

[73] Mondal S, Adhikari N, Banerjee S, et al. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: a minireview. Eur J Med Chem. 2020;194:112260.

[74] Lv Y, Zhao X, Zhu L, et al. Targeting intracellular MMPs efficiently inhibits tumor metastasis and angiogenesis. Theranostics. 2018;8(10):2830–2845.

[75] Webb AH, Gao BT, Goldsmith ZK, et al. Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma. BMC Cancer. 2017;17(1):434.

[76] Stemmler MP, Eccles RL, Brabletz S, et al. Non-redundant functions of EMT transcription factors. Nat Cell Biol. 2019;21(1):102–112.

[77] Georgakopoulos-Soares I, Chartoumpekis DV, Kyriazopoulou V, et al. EMT factors and metabolic pathways in cancer. Front Oncol. 2020;10:499.

[78] Gyamfi J, Eom M, Koo J-S, et al. Multifaceted roles of interleukin-6 in adipocyte-breast cancer cell interaction. Transl Oncol. 2018;11(2):275–285.

[79] Goossens S, Vandamme N, Van Vlierbergh P, et al. EMT transcription factors in cancer development re-evaluated: beyond EMT and MET. Biochim Biophys Acta Rev Cancer. 2017;1868(2):584–591.

[80] Even-Ram S, Yamada KM. Cell migration in 3D matrix. Curr Opin Cell Biol. 2005;17(5):524–532.

[81] Ley K, Laudanna C, Cybulsky MI, et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7(9):678–689.

[82] Samaniego R, Gutiérrez-González A, Gutiérrez-Seijo A, et al. CCL20 expression by tumor-associated macrophages predicts progression of human primary cutaneous melanoma. Cancer Immunol Res. 2018;6(3):267–275.

[83] Liu W, Wang W, Wang X, et al. Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20–CCR6 axis. Cancer Lett. 2020;472:59–69.

[84] Kadamoto S, Izumi K, Hiratsuka K, et al. Tumor-associated macrophages induce migration of renal cell carcinoma cells via activation of the CCL20–CCR6 axis. Cancers (Basel). 2020;12(1):89.

[85] Wang B, Shi L, Sun X, et al. Production of CCL20 from lung cancer cells induces the cell migration and proliferation through PI3K pathway. J Cell Mol Med. 2016;20(5):920–929.

[86] Kim KY, Baek A, Park YS, et al. Adipocyte culture medium stimulates invasiveness of MDA-MB-231 cell via CCL20 production. Oncol Rep. 2009;22(6):1497–1504.
[87] Lee SK, Park -K-K, Kim H-J, et al. Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis. Sci Rep. 2017;7(1):9610.

[88] Zhong X, Xiu H, Bi Y, et al. Targeting elf5A2 inhibits prostate carcinogenesis, migration, invasion and metastasis in vitro and in vivo. Bioengineered. 2020;11(1):619–627.

[89] Yin D, Lu X. Silencing of long non-coding RNA HCP5 inhibits proliferation, invasion, migration, and promotes apoptosis via regulation of miR-299-3p/SMA5 axis in gastric cancer cells. Bioengineered. 2021;12(1):225–239.

[90] Han G, Wu D, Yang Y, et al. CrkI mediates CCL20/CCL6-induced EMT in gastric cancer. Cytokine. 2015;76(2):163–169.

[91] Zeng W, Chang H, Ma M, et al. CCL20/CCL6 promotes the invasion and migration of thyroid cancer cells via NF-kappa B signaling-induced MMP-3 production. Exp Mol Pathol. 2014;97(1):184–190.

[92] Chen W, Qin Y, Wang D, et al. CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. PLoS Biol. 2018;16(7):e2005869.

[93] Wang D, Yang L, Yu W, et al. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/C/EBPB/NF-kB signaling. J Immunother. Cancer. 2019;7(1):215.

[94] Fattore L, Sacconi A, Mancini R, et al. MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma. Cytokine Growth Factor Rev. 2017;36:39–48.

[95] Dama P, Tang M, Fulton N, et al. Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer. 2019;7(1):175.

[96] Wang D, Yang L, Yu W, et al. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/C/EBPB/NF-kB signaling. J Immunother Cancer. 2019;7(1):215.

[97] Pusztai L, Mendoza TR, Reuben JM, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004;25(3):94–102.

[98] Gales D, Clark C, Manne U, et al. The chemokine CXCL8 in carcinogenesis and drug response. ISRN Oncol. 2013;2013:859154.

[99] Zhang G, Luo X, Zhang W, et al. CXCL-13 regulates resistance to 5-fluorouracil in colorectal cancer. Cancer Res Treat. 2020;52(2):622–633.

[100] Nguyen LV, Vanner R, Dirks P, et al. Cancer stem cells: an evolving concept. Nat Rev Cancer. 2012;12(2):133–143.

[101] Rich JN, Bao S. Chemotherapy and cancer stem cells. Cell Stem Cell. 2007;1(4):353–355.

[102] Kachalaki S, Ebrahimi M, Mohamed Khosroshahi L, et al. Cancer chemoresistance; biochemical and molecular aspects: a brief overview. Eur J Pharm Sci. 2016;89:20–30.

[103] Chen M, Su J, Feng C, et al. Chemokine CCL20 promotes the paclitaxel resistance of CD44+CD117+ cells via the notch1 signaling pathway in ovarian cancer. Mol Med Rep. 2021;24(3):635.

[104] Wang X, Zhang H, Chen X, et al. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2:141–160.

[105] Li T, Quan H, Zhang H, et al. Silencing cyclophilin A improves insulin secretion, reduces cell apoptosis, and alleviates inflammation as well as oxidant stress in high glucose-induced pancreatic β-cells via MAPK/NF-κb signaling pathway. Bioengineered. 2020;11(1):1047–1057.

[106] Liu T, Zhang L, Joo D, et al. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023.

[107] Gao W, Gao J, Chen L, et al. Targeting XIST induced apoptosis of human osteosarcoma cells by activation of NF-κB/PUMA signal. Bioengineered. 2019;10(1):261–270.

[108] Reedijk M. Notch signaling and breast cancer. Adv Exp Med Biol. 2012;727:241–257.

[109] Yao Y, Li X, Cheng L, et al. Circular RNA FAT atypical cadherin 1 (circFAT1)/microRNA-525-5p/spindle and kinetochore-associated complex subunit 1 (SKA1) axis regulates oxaliplatin resistance in breast cancer by activating the notch and Wnt signaling pathway. Bioengineered. 2021;12(1):4032–4043.

[110] Obata Y, Kimura S, Nakato G, et al. Epithelial-stromal interaction via notch signaling is essential for the full maturation of gut-associated lymphoid tissues. EMBO Rep. 2014;15(12):1297–1304.

[111] Küçükköse C, Ö: YO. Effects of notch signalling on the expression of SEMA3C, HMG2A, CXCL14, CXCR7, and CCL20 in breast cancer. Turk J Biol. 2019;43(1):70–76.

[112] Kirshberg S, Izhar U, Amir G, et al. Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. PLoS One. 2011;6(9):e24856–e24856.

[113] Lauriola I, Serini S, Granone P, et al. Hu/elav RNA-binding protein HuR regulates parathyroid hormone related peptide expression in human lung adenocarcinoma cells. Histol Histopathol. 2013;28(9):1205–1216.

[114] Woo HH, Zhou Y, Xi Y, et al. Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer. Oncogene. 2009;28(9):1176–1186.

[115] Jayaraman S, Doucet M, Kominsky SL, et al. Down-regulation of CITED2 attenuates breast tumor growth, vessel formation and TGF-β-induced expression of VEGFα. Oncotarget. 2017;8(4):6169–6178.
[116] Minemura H, Takagi K, Sato A, et al. CITED2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance. Cancer Sci. 2016;107(12):1898–1908.

[117] Jayaraman S, Doucet M, Lau WM, et al. CITED2 modulates breast cancer metastatic ability through effects on IKKa. Mol Cancer Res. 2016;14(8):730–739.

[118] Bakker WJ, Harris IS, Mak TW, et al. FOXO3a is activated in response to hypoxic stress and inhibits HIF1-induced apoptosis via regulation of CITED2. Mol Cell. 2007;28(6):941–953.

[119] Cruceriu D, Baldasici O, Balacescu O, et al. The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches. Cell Oncol. 2020;43(1):1–18.

[120] Iwamoto S, Kido M, Aoki N, et al. TNF-α is essential in the induction of fatal autoimmune hepatitis in mice through upregulation of hepatic CCL20 expression. Clin Immunol. 2013;146(1):15–25.